Keywords: داکومیتینیب; Afatinib; Chemotherapy; Dacomitinib; Epidermal growth factor receptor; Erlotinib; Gefitinib; Non-small cell lung cancer; Pharmacokinetics; Tyrosine kinase inhibitors;
مقالات ISI داکومیتینیب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib
Keywords: داکومیتینیب; Adenocarcinoma; Dacomitinib; EGFR mutation; Lung cancer; Tyrosine kinase inhibitor;
Identification of a novel autophagic inhibitor cepharanthine to enhance the anti-cancer property of dacomitinib in non-small cell lung cancer
Keywords: داکومیتینیب; Cepharanthine; Autophagy; Lysosome; Dacomitinib; NSCLC;
Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer
Keywords: داکومیتینیب; Dacomitinib; Skin cancer; Skin squamous cell carcinoma;
Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters
Keywords: داکومیتینیب; Dacomitinib; Multidrug resistance (MDR); ATP-binding cassette (ABC) transporter; P-glycoprotein (P-gp/ABCB1); Breast cancer resistance protein (BCRP/ABCG2); MDR; multidrug resistance; ABC; ATP-binding cassette; EGFR; epidermal growth factor receptor; TK;
Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042)
Keywords: داکومیتینیب; NSCLC; non-small-cell lung cancer; HER; Human Epidermal Growth Factor Receptor; EGFR; Epidermal Growth Factor Receptor; Dacomitinib; Non-small-cell lung cancer; Dose interruption; Pharmacokinetic; Supportive care;
Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials
Keywords: داکومیتینیب; Afatinib; Dacomitinib; Erlotinib; Gefitinib; Icotinib;
Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study
Keywords: داکومیتینیب; Non-small cell; Dacomitinib; Crizotinib; EGFR TKI resistance; Biomarkers;
Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non-Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib: A Phase I/II Trial
Keywords: داکومیتینیب; Dacomitinib; Non-small-cell lung cancer; Erlotinib; Gefitinib; Refractory;
Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma
Keywords: داکومیتینیب; EGFR mutations; Secondary resistance; Gefitinib; Erlotinib; Afatinib; Dacomitinib; Tyrosine kinase inhibitors; Non-small-cell lung cancer